Samuel C. Blackman Sells 10,000 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) insider Samuel C. Blackman sold 10,000 shares of the firm’s stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $16.01, for a total value of $160,100.00. Following the transaction, the insider now directly owns 1,184,662 shares in the company, valued at $18,966,438.62. The sale was disclosed in a document filed with the SEC, which is available at this link.

Day One Biopharmaceuticals Stock Up 4.6 %

NASDAQ DAWN opened at $16.52 on Friday. Day One Biopharmaceuticals, Inc. has a twelve month low of $9.67 and a twelve month high of $17.85. The firm has a market capitalization of $1.44 billion, a PE ratio of -6.94 and a beta of -1.48. The stock’s 50 day moving average is $15.16 and its 200 day moving average is $13.54.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its quarterly earnings results on Monday, February 26th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.07). On average, research analysts anticipate that Day One Biopharmaceuticals, Inc. will post -2.66 earnings per share for the current year.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the stock. RA Capital Management L.P. boosted its holdings in Day One Biopharmaceuticals by 10.9% in the second quarter. RA Capital Management L.P. now owns 7,809,852 shares of the company’s stock worth $93,250,000 after acquiring an additional 769,230 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Day One Biopharmaceuticals by 3.0% in the fourth quarter. Vanguard Group Inc. now owns 4,769,746 shares of the company’s stock worth $69,638,000 after purchasing an additional 139,992 shares during the last quarter. Franklin Resources Inc. raised its stake in shares of Day One Biopharmaceuticals by 4.2% in the fourth quarter. Franklin Resources Inc. now owns 4,236,795 shares of the company’s stock worth $61,857,000 after purchasing an additional 169,463 shares during the last quarter. Braidwell LP raised its stake in shares of Day One Biopharmaceuticals by 13.5% in the fourth quarter. Braidwell LP now owns 4,215,573 shares of the company’s stock worth $61,547,000 after purchasing an additional 500,000 shares during the last quarter. Finally, BlackRock Inc. raised its stake in shares of Day One Biopharmaceuticals by 57.8% in the second quarter. BlackRock Inc. now owns 3,564,733 shares of the company’s stock worth $42,563,000 after purchasing an additional 1,306,238 shares during the last quarter. 87.95% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

DAWN has been the topic of a number of research reports. Oppenheimer reissued a “market perform” rating on shares of Day One Biopharmaceuticals in a report on Tuesday, February 27th. The Goldman Sachs Group decreased their price target on Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating on the stock in a research note on Tuesday, February 27th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $40.60.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.